MIT’s Protein Champion Against Superbugs

Scientists working in a laboratory with microscopes and test tubes

Your gut harbors a protein warrior that doesn’t just defend against dangerous bacteria—it traps them like flies on paper while simultaneously building an impenetrable fortress wall.

Story Snapshot

MIT researchers discovered intelectin-2, a human-produced gut protein that both kills antibiotic-resistant bacteria and reinforces the intestinal mucus barrier
The protein works by binding to sugar molecules on bacterial surfaces, neutralizing pathogens like Staphylococcus aureus and Klebsiella pneumoniae
Intelectin-2 operates through a dual mechanism: cross-linking mucin proteins to strengthen gut defenses while directly trapping and destroying invading microbes
The discovery opens new therapeutic pathways for inflammatory bowel disease and combating antimicrobial resistance without traditional antibiotics
Published March 16, 2026, in Nature Communications, the findings challenge previous assumptions about how our bodies defend the gastrointestinal tract

The Sweet Science of Bacterial Destruction

Laura Kiessling, Novartis Professor of Chemistry at MIT, led a team that identified intelectin-2’s remarkable capabilities after screening various lectin proteins for gastrointestinal activity. The protein functions as a molecular Swiss Army knife, exploiting a vulnerability bacteria cannot easily evolve away from: their sugar-coated surfaces. Intelectin-2 latches onto galactose molecules present on both mucin proteins and bacterial membranes, creating a double-edged defense system. This targeting strategy proves devastatingly effective against some of medicine’s most stubborn adversaries, including strains that laugh off conventional antibiotics.

The research team, including lead authors Amanda Dugan and Deepsing Syangtan, demonstrated how intelectin-2 operates through complementary mechanisms that previous studies overlooked. In humans, Paneth cells in the small intestine produce this protein, while in mice, goblet cells manufacture it during inflammatory responses. This distinction matters because it reveals how the body deploys intelectin-2 strategically, ramping up production when threats emerge. The protein doesn’t simply kill bacteria—it creates a scaffolding effect, linking mucin molecules together to fortify the mucus layer that separates our gut lining from potentially harmful microorganisms.

When Defense Becomes Disease

The discovery carries profound implications for inflammatory bowel disease patients, where intelectin-2 levels swing wildly off balance. Too little of the protein, and the mucus barrier crumbles, allowing bacterial invasion that triggers inflammation. Too much, and the delicate ecosystem of beneficial gut bacteria suffers disruption, a condition called dysbiosis that creates its own cascade of health problems. This Goldilocks dilemma presents both opportunity and challenge for therapeutic development. Kiessling’s team recognizes that future treatments must carefully modulate intelectin-2 levels rather than simply flooding the gut with the protein.

The implications extend beyond IBD into the escalating crisis of antibiotic resistance. Traditional antibiotics face diminishing returns as bacteria evolve countermeasures, but intelectin-2 exploits structural features bacteria cannot easily modify without compromising their own survival. This protein represents what Kiessling calls “a fundamentally new strategy” that harnesses innate human defenses rather than introducing external chemical agents. The approach aligns with a broader shift in medical thinking: working with the body’s existing toolkit rather than against it, respecting the wisdom of biological systems refined over millions of years of evolution.

The Protein Injection Confusion

Separate research by the Helmholtz consortium identified a different mechanism where bacteria themselves inject proteins into human cells, influencing immune responses and potentially contributing to Crohn’s disease. This bacterial injection system operates inversely to intelectin-2’s defensive role, highlighting the complex dance between human hosts and microbial inhabitants. The distinction matters because it underscores how oversimplified narratives about “good bacteria” and “bad bacteria” miss the nuanced reality of gut ecology. Some microbes protect us, others attack, and many occupy gray zones where context determines their impact on health.

Scientists find gut bacteria inject proteins that control your immune system

Gut bacteria aren’t just passive passengers—they can actively send proteins straight into our cells. Using microscopic injection systems, even harmless microbes can influence immune responses and…

— The Something Guy 🇿🇦 (@thesomethingguy) March 27, 2026

The biotechnology and pharmaceutical sectors now possess new targets for drug development through lectin engineering. Rather than designing synthetic molecules from scratch, researchers can potentially enhance or mimic intelectin-2’s natural capabilities. This approach offers economic advantages—building on proven biological mechanisms reduces development risk—while addressing urgent public health needs. The convergence of microbiome research, antimicrobial resistance concerns, and chronic disease management creates a perfect storm of opportunity for innovations that leverage our body’s inherent defensive systems. For patients suffering from conditions linked to gut barrier dysfunction, these discoveries translate into hope grounded in rigorous science rather than empty promises.